Long-term safety remains a key concern when selecting antihypertensive therapy, particularly for agents used as first-line treatment. Calcium channel blockers (CCBs) are widely prescribed, but their long-term safety and effectiveness across clinical outcomes require careful evaluation.

A systematic review published in Drug, Healthcare and Patient Safety analyzed 29 studies, including randomized controlled trials (RCTs), cohort studies, and case-control studies, to assess outcomes associated with ≥1 year of CCB use in adults with hypertension (HTN). Studies compared CCBs with other antihypertensive therapies or placebo and evaluated systemic safety and cardiovascular effectiveness. Study quality was assessed using the Jadad and Newcastle-Ottawa Scales.

Long-term CCB use was generally associated with a favorable safety profile, with most reported adverse effects considered manageable. Evidence for renal protective effects remained inconsistent. Some studies reported a slight increase in new-onset diabetes, while findings related to breast cancer were inconclusive. A modest reduction in fracture risk was observed in some analyses, and other systemic effects, including metabolic and reproductive changes, were typically mild.

CCB use was consistently associated with reduced stroke incidence. However, findings for myocardial infarction (MI), heart failure (HF), and transient ischemic attack (TIA) were inconsistent across studies.

Overall, CCBs appear to maintain long-term safety with consistent benefit for stroke outcomes, although variability across other cardiovascular endpoints warrants cautious interpretation.